Snapshot from Jul 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Strand Life Sciences patents blood...
Tech patent grant

Strand Life Sciences patents blood cancer test

Analysis based on 12 articles · First reported Jul 07, 2026 · Last updated Jul 07, 2026

Sentiment
30
Attention
2
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The patent strengthens Reliance Industries — Strand Life Sciences' intellectual property portfolio and reinforces Reliance Industries' position in precision oncology. It could boost investor confidence in Reliance's healthcare ventures and potentially open new revenue streams through licensing or partnerships.

Healthcare Biotechnology Diagnostics
Event Summary

Reliance Industries — Strand Life Sciences, a subsidiary of Reliance Industries, has been granted an Indian patent for an integrated platform that enables early cancer detection from a simple blood test using cell-free DNA (cfDNA) analysis. The platform combines genome sequencing, methylation and fragmentomic feature extraction, and machine learning to detect cancer and predict its tissue of origin. The patent covers innovations in capturing methylation patterns with minimal loss, enabling sensitive early-stage diagnosis. With over 1.5 million new cancer cases annually in India, the technology aims to make screening more accessible and scalable. CEO Ramesh Hariharan stated the patent reflects commitment to AI-enabled liquid biopsy technologies.

Key Actions
90 Reliance Industries — Strand Life Sciences secured patent
Entities Involved
subs
Reliance Industries — Strand Life Sciences
Reliance Industries — Strand Life Sciences is the patent holder and innovator; this patent enhances its IP portfolio and credibility in liquid biopsy, potentially accelerating commercialization and partnerships.
Importance 100.0 Sentiment 70.0
stock
Reliance Industries
As parent company, Reliance Industries benefits from the subsidiary's innovation, strengthening its healthcare division and aligning with India's growing diagnostic market.
Importance 80.0 Sentiment 60.0
cnt
India
India faces a high cancer burden; this technology could improve early detection rates and reduce healthcare costs, aligning with government efforts to expand affordable diagnostics.
Importance 50.0 Sentiment 40.0
per
Ramesh Hariharan
CEO of Reliance Industries — Strand Life Sciences; his leadership and public statements highlight the company's strategic direction in AI-enabled diagnostics.
Importance 30.0 Sentiment 50.0
Relationships
Reliance Industries related ↔ India
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.